--- title: "Repligen Corporation (RGEN.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/RGEN.US.md" symbol: "RGEN.US" name: "Repligen Corporation" industry: "生命科學工具與服務" --- # Repligen Corporation (RGEN.US) | Item | Detail | |------|--------| | Industry | 生命科學工具與服務 | | Location | 美股市場 | | Website | [www.repligen.com](https://www.repligen.com) | ## Company Profile Repligen Corporation 是一家生命科學公司,在北美、歐洲、亞太地區及國際市場開發和商業化生物處理技術和系統。它提供的產品包括蛋白 A 配體,這些配體是蛋白 A 親和色譜樹脂的結合成分;以及細胞培養生長因子產品。該公司還提供色譜產品,包括用于生物制品純化的 OPUS 預裝色譜柱;以及用于高通量工藝開發篩選、病毒去除驗證研究和色譜工藝縮放驗證的 OPUS 小規模色譜柱,以及 ELISA 測試試劑盒。此外,它還提供過濾產品,如 XCell ATF 細胞保留系統,這是一種用于上遊灌注和細胞培養處理的過濾設備;TangenX 平板盒,這些盒子用于下遊生物藥物濃縮、緩衝液交換和配方過程;... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-20T04:30:13.000Z **Overall: B (0.40)** **Industry**: Life Sciences Tools and Services | Metric | Value | |--------|-------| | Industry Ranking | 7 / 62 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 11.74% | | | Net Profit YoY | 121.47% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 3.71 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 7.72B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 707.89M | | **Multi Score**: B #### Profit Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 0.08% | D | | Profit Margin | 0.25% | C | | Gross Margin | 53.24% | B | #### Growth Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 11.74% | B | | Net Profit YoY | 121.47% | A | | Total Assets YoY | 3.29% | C | | Net Assets YoY | 3.29% | C | #### Cash Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 40730.15% | A | | OCF YoY | 11.74% | B | #### Operating Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.25 | D | #### Debt Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 28.75% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Repligen Corporation", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "C", "indicators": [ { "name": "ROE", "value": "0.08%", "rating": "D" }, { "name": "Profit Margin", "value": "0.25%", "rating": "C" }, { "name": "Gross Margin", "value": "53.24%", "rating": "B" } ] }, { "name": "Growth", "grade": "B", "indicators": [ { "name": "Revenue YoY", "value": "11.74%", "rating": "B" }, { "name": "Net Profit YoY", "value": "121.47%", "rating": "A" }, { "name": "Total Assets YoY", "value": "3.29%", "rating": "C" }, { "name": "Net Assets YoY", "value": "3.29%", "rating": "C" } ] }, { "name": "Cash", "grade": "A", "indicators": [ { "name": "Cash Flow Margin", "value": "40730.15%", "rating": "A" }, { "name": "OCF YoY", "value": "11.74%", "rating": "B" } ] }, { "name": "Operating", "grade": "D", "indicators": [ { "name": "Turnover", "value": "0.25", "rating": "D" } ] }, { "name": "Security", "grade": "B", "indicators": [ { "name": "Gearing Ratio", "value": "28.75%", "rating": "B" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A | | 02 | 安捷倫科技 (US.A) | A | C | B | C | C | B | | 03 | 沃特世 (US.WAT) | A | B | B | C | C | B | | 04 | 藥明生物(ADR) (US.WXXWY) | B | B | D | A | B | B | | 05 | 西氏醫藥服務 (US.WST) | B | B | B | B | C | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 4444.31 | 23/59 | 5388.11 | 5208.35 | 4732.24 | | PB | 3.71 | 38/59 | 4.35 | 3.80 | 3.39 | | PS (TTM) | 10.91 | 50/59 | 12.99 | 11.52 | 10.36 | | Dividend Yield | 0.00% | - | - | - | - | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-05T05:00:00.000Z Total Analysts: **21** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 14 | 67% | | Overweight | 3 | 14% | | Hold | 4 | 19% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 137.72 | | Highest Target | 220.00 | | Lowest Target | 160.00 | ## References - [Company Overview](https://longbridge.com/en/quote/RGEN.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/RGEN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/RGEN.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.